Evidence map›Paper›PMID 34270923›Full record

ReviewThe Lancet. Respiratory medicine2021

Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines.

Matthew Jankowich, Bradley A Maron, Gaurav Choudhary

Open access · greenAbstract readReview
In one paragraph

Review in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Matthew JankowichProvidence Veterans Affairs Medical Center, Providence, RI, USA; Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Bradley A MaronVeterans Affairs Boston Healthcare System, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Gaurav ChoudharyProvidence Veterans Affairs Medical Center, Providence, RI, USA; Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: gaurav_choudhary@brown.edu.
Providence VA Medical Center · USBrigham and Women's Hospital · US

Funding

Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertensionR01HL139613 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Sirano Dhe-Paganon, Bradley Maron · 2018 to 2026
$4.1M
NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertensionR01HL153502 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2020 to 2023
$1.7M
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertensionR01HL155096 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2021 to 2024
$1.6M
Role of Endothelial Anoctamin-1 in Pulmonary Arterial HypertensionR01HL148727 · NHLBI · OCEAN STATE RESEARCH INSTITUTE, INC. · PI CHOUDHARY, GAURAV · 2019 to 2022
$1.6M
Network medicine, risk stratification, and pulmonary hypertensionR21HL145420 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARON, BRADLEY · 2019 to 2020
$287k
CSRD VA I01 CX001892NHLBI NIH HHS R01 HL139613NHLBI NIH HHS R01 HL148727NHLBI NIH HHS R01 HL153502NHLBI NIH HHS R01 HL155096NHLBI NIH HHS R21 HL145420NHLBI NIH HHS U54 HL119145
6 · The paper itself

Abstract

Pulmonary hypertension is associated with increased morbidity and mortality, and growing evidence suggests that even mild elevations in pulmonary artery pressure estimated with echocardiography are linked to increased mortality. In healthy individuals who undergo right heart catheterisation, the average pulmonary artery systolic pressure ranges from 17 mm Hg to 25 mm Hg; on echocardiography, estimated pulmonary artery systolic pressure of more than 30 mm Hg is outside the normal range for most healthy individuals. Increased pulmonary artery systolic pressure (>30 mm Hg) is reported on more than 40% of clinically indicated echocardiograms, often in the presence of metabolic and cardiopulmonary comorbidities, and is associated with a 5-year mortality of 25-40%. However, current guidelines do not sufficiently highlight risk and risk-reduction approaches for the sizable patient population with elevated pulmonary artery pressure who do not have underlying severe pulmonary vascular disease such as pulmonary arterial hypertension. Increased awareness of this frequently reported high-risk echocardiographic finding, and multidisciplinary risk-reduction approaches for patients with metabolic and cardiopulmonary comorbidities and elevated pulmonary artery pressure, are urgently needed.

Indexed as

Hypertension, PulmonaryPulmonary ArteryBlood PressureEchocardiographyEchocardiography, DopplerHumans

Identifiers

PMID34270923
PMCPMC8936511
OpenAlexW3179453745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.